Article
Cell Biology
Yi Jiang, Zhenhao Zeng, Situ Xiong, Ming Jiang, Gaomin Huang, Chiyu Zhang, Xiaoqing Xi
Summary: The study identified two distinct immune clusters in BLCA patients, characterized by high and low ImmuneScores. CD96 and IBSP were identified as prognostic genes. ImmuneScoreH showed inactivation of innate immune cell chemotaxis, while ImmuneScoreL exhibited low tumor antigen load as a potential immune escape mechanism.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Libo Yang, Chunyan Li, Yang Qin, Guoying Zhang, Bin Zhao, Ziyuan Wang, Youguang Huang, Yong Yang
Summary: A novel prognostic model based on nine ferroptosis-related genes demonstrated superior predictive performance in bladder cancer patients. The risk score was found to be an independent risk factor associated with overall survival (OS).
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Lianmin Luo, Fenghua Li, Binbin Gong, Ping Xi, Wenjie Xie
Summary: This study established a prognostic model based on cellular senescence-related genes in bladder cancer (BCa), which showed reliable predictive power for patient survival. Functional analysis revealed differences in immune-related pathways activity and immune cell infiltration between the two risk groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Zongcai Yan, Meiling He, Lifeng He, Liuxia Wei, Yumei Zhang
Summary: This study established a six-gene prognostic model for HCC by analyzing DEGs, which could help determine prognosis and serve as biomarkers for personalized disease management in HCC patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Lijuan Gao, Ruimin Ren, Jing Shen, Jiayi Hou, Junya Ning, Yanlin Feng, Meiyue Wang, Lifei Wu, Yaojun Sun, Huang Wang, Deping Wang, Jimin Cao
Summary: This study identified the expressions and biological functions of the 2', 5'-oligoadenylate synthetase (OAS) gene family in bladder cancer (BLCA). The highly expressed OAS genes in BLCA were found to be associated with immune cell infiltration in the tumor microenvironment and predicted better overall survival. These findings provide new insights into the diagnosis, treatment, and prognosis of BLCA.
Article
Biochemistry & Molecular Biology
Orla Howe, Lisa White, Daniel Cullen, Grainne O'Brien, Laura Shields, Jane Bryant, Emma Noone, Shirley Bradshaw, Marie Finn, Mary Dunne, Aoife M. Shannon, John Armstrong, Brendan McClean, Aidan Meade, Christophe Badie, Fiona M. Lyng
Summary: Validation of a new 4-gene signature panel using G2 chromosomal radiosensitivity assay revealed significant differences in radiation response post-exposure, while some prostate cancer donors showed altered response due to Androgen Deprivation Therapy, suggesting intra-individual heterogeneity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Guanwen Zhou, Guoliang Qin, Zhaocun Zhang, Haifeng Zhao, Linlin Xue
Summary: In this study, we constructed a risk model based on metabolism- and immune-related genes in BLCA, which effectively predicted patient prognosis and immunotherapy response.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Gomathi Venkatasubramanian, Devaki A. Kelkar, Susmita Mandal, Mohit Kumar Jolly, Madhura Kulkarni
Summary: Breast cancers are treated differently based on ER/PR or HER2 expression, while targeted therapy for triple-negative breast cancers remains challenging. YAP1 as a potential marker may help identify personalized treatment strategies for TNBC.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Genetics & Heredity
Fei Xu, Qianqian Tang, Yejinpeng Wang, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao
Summary: This study identified and validated a six-gene signature for predicting cancer-specific survival in patients with bladder cancer. Functional analysis showed enrichment in lipid metabolism and cell division processes. The six-gene signature was found to be an independent prognostic factor and had predictive ability for cancer-specific survival prognosis.
FRONTIERS IN GENETICS
(2021)
Article
Immunology
Yuchen Bai, Qi Zhang, Feng Liu, Jing Quan
Summary: A novel cuproptosis-related lncRNA signature was identified that could predict the prognosis and immune landscape of BLCA. This signature not only had a higher diagnostic efficiency compared to other clinical features, but also had a good performance in predicting the 1-year, 3-year, and 5-year overall survival rate in BLCA. Patients with a low risk score seemed to be associated with an inflamed tumor immune microenvironment and had a higher TMB level than those with a high risk score.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Adam B. B. Weiner, Yang Liu, Alex Hakansson, Xin Zhao, James A. A. Proudfoot, Julian Ho, J. J. H. H. Zhang, Eric V. V. Li, R. Jeffrey Karnes, Robert B. B. Den, Amar U. U. Kishan, Robert E. E. Reiter, Anis A. A. Hamid, Ashely E. E. Ross, Phuoc T. T. Tran, Elai Davicioni, Daniel E. E. Spratt, Gerhardt Attard, Tamara L. L. Lotan, Melvin Lee Kiang Chua, Christopher J. J. Sweeney, Edward M. M. Schaeffer
Summary: A prostate subtyping classifier (PSC) was created by analyzing expression profiles from over 100,000 prostate tumors, identifying four subtypes with distinct biological and clinical features.
Article
Oncology
Xiaotao Li, Shi Fu, Yinglong Huang, Ting Luan, Haifeng Wang, Jiansong Wang
Summary: A novel MRG signature was successfully constructed to predict the prognosis of BC patients, which may contribute to guiding clinical treatment decisions.
Article
Immunology
Zhao Zhang, Yongbo Yu, Peng Li, Meilan Wang, Wei Jiao, Ye Liang, Haitao Niu
Summary: A novel immune-related gene signature was developed to predict the prognosis of bladder cancer and guide treatment. Gene expression and clinical data were analyzed to identify genes associated with EMT and metabolic status, which were used to construct the predictive signature.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Bingqi Dong, Jiaming Liang, Ding Li, Wenping Song, Jinbo Song, Mingkai Zhu, Shiming Zhao, Yongkang Ma, Tiejun Yang
Summary: A prognostic signature associated with the homeobox gene family has been developed for bladder cancer, showing good accuracy and consistency in predicting patient prognosis and response to immunotherapy. This signature could potentially serve as a biomarker and treatment target for BLCA patients.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
Steve E. Kalloger, Joanna M. Karasinska, Martin S. Keung, Danielle L. Thompson, Julie Ho, Christine Chow, Dongxia Gao, James T. Topham, Cassia Warren, Hui-Li Wong, Michael Kuan-Ching Lee, Daniel J. Renouf, David F. Schaeffer
Summary: The study examined the epithelial and stromal components in pancreatic ductal adenocarcinoma (PDAC) using laser capture microdissected (LCM) samples, revealing that the stromal component had independent prognostic differences. Specific gene expression differences in the epithelium and stroma may help improve prognostication for PDAC.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Arun A. Azad, Andrew J. Armstrong, Antonio Alcaraz, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Boris Alekseev, Taro Iguchi, Neal D. Shore, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, Arnulf Stenzl
Summary: In patients with metastatic hormone-sensitive prostate cancer, enzalutamide plus androgen deprivation therapy (ADT) demonstrated overall clinical benefit, regardless of prior local and systemic treatment, disease volume, and risk factors.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Urology & Nephrology
Mireia Musquera, Lluis Peri, Maurizio D'Anna, Tarek Ajami, Maria Jose Ribal, Antoni Vilaseca, Ignacio Revuelta, Ricardo Alvarez-Vijande, Ana Palacios, Fritz Diekmann, Conchita Monsalve, Beatriz Tena, Laura Izquierdo, Raul Martos, David Paredes, Joan Beltran, Federico Oppenheimer, Antonio Alcaraz
Summary: This study retrospectively observed the experience and results of minimally invasive living-donor nephrectomies (MILDN) performed between March 2002 and March 2020. The results showed that MILDN techniques are safe for donors and grafts, with low complication rates.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Medical Laboratory Technology
Denis Horgan, Mario Plebani, Matthias Orth, Elizabeth Macintyre, Stan Jackson, Jonathan A. Lal, France Dube, Marta Kozaric, Birute Tumiene, Roberto Salgado, Jack A. Schalken, Ettore D. Capoluongo, Marta Carnielli
Summary: The background of this debate is the EU's decision to tighten controls on the devices and diagnostics sector, which led to the adoption of a regulation with a schedule for implementation. The recent deferral of implementation deadlines has exposed ongoing challenges in terms of awareness and implementation of the regulation across Europe. There is limited awareness of the In Vitro Diagnostic Regulation (IVDR) and the different national systems involved, which poses risks for patient and consumer access to in vitro diagnostics (IVDs). The proposed solutions so far remain more aspirational than practical.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Oncology
Nikoletta Vidra, Ivy Beeren, Moniek van Zutphen, Katja K. Aben, Ellen Kampman, J. Alfred Witjes, Antoine G. van Der Heijden, Lambertus A. Kiemeney, Alina Vrieling
Summary: Although the evidence is limited, adherence to the WCRF/AICR lifestyle recommendations is associated with improved health-related quality of life in patients with NMIBC.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Jeroen van Dorp, Christodoulos Pipinikas, Britt B. M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Toine G. van der Heijden, Nitzan Rosenfeld, Bas W. G. van Rhijn, Greg Jones, Michiel S. van der Heijden
Summary: Cohort 1 of the phase 1B NABUCCO trial showed high pCR rates with preoperative ipilimumab plus nivolumab in stage III UC. In cohort 2, dose adjustment was aimed to optimize responses. Absence of ctDNA in plasma can predict PFS in stage III UC patients treated with high-dose ipilimumab plus nivolumab.
Article
Urology & Nephrology
Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clementine Le Magnen, Nora M. Navone, Jack A. Schalken, Yuzhuo Wang, Wytske M. van Weerden, Eva Corey, John T. Isaacs, Peter S. Nelson, Gail P. Risbridger
Summary: This Perspective article discusses patient-derived xenografts (PDXs) of prostate cancer and their utility in basic and preclinical research. The authors emphasize the need for more diverse and accessible PDX models to reflect patient diversity and study emerging treatment strategies and mechanisms of resistance. Collaboration and data sharing can greatly enhance the use of PDXs in prostate cancer research.
NATURE REVIEWS UROLOGY
(2023)
Article
Oncology
Gerben Lassche, Wim van Boxtel, Tilly W. Aalders, Onno van Hooij, Adriana C. H. van Engen-van Grunsven, Gerald W. Verhaegh, Carla M. L. van Herpen, Jack A. Schalken
Summary: This study successfully established comprehensively characterized short-term PDO models for three subtypes of SGC, which closely resemble the parental tissue in phenotypic and genotypic aspects.
Article
Oncology
Gerben Lassche, Adriana C. H. van Engen-van Grunsven, Onno van Hooij, Tilly W. Aalders, Jetty A. M. Weijers, Emiliano Cocco, Alexander Drilon, Alexander Hoischen, Kornelia Neveling, Jack A. Schalken, Gerald W. Verhaegh, Carla M. L. van Herpen
Summary: The use of anticancer drugs targeting specific molecular tumor characteristics is increasing, but selecting patients to benefit from these treatments remains challenging. Organoid cultures have been proposed as a suitable method to test drug responses in vitro. This study presents a case of secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion and corresponding organoid cultures. The cultures initially responded to TRK targeting therapy, but later developed resistance. This case highlights the advancements in precision oncology and the limitations of using organoids in predicting treatment response.
Article
Biochemistry & Molecular Biology
Levi Groen, Viktor Yurevych, Harshitha Ramu, Johnny Chen, Lianne Steenge, Sabrina Boer, Renske Kuiper, Frank P. Smit, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Summary: This study identified differentially expressed lncRNAs in castration-resistant prostate cancer (CRPC) and focused on the functional characterization of NAALADL2-AS2, a novel CRPC-upregulated lncRNA. Knockdown of NAALADL2-AS2 decreased cell viability and increased caspase activity, suggesting its role as a pro-survival signal in prostate cancer cells under targeted hormone therapy.
Article
Biochemistry & Molecular Biology
Levi Groen, Iris Kloots, David Englert, Kelly Seto, Lana Estafanos, Paul Smith, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Summary: The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is well recognized. The earliest methods for enriching CTCs relied on antibody-based positive selection, but it has limitations in capturing the heterogeneity of cancer. This study used the recently FDA-approved Parsortix (R) technology to enrich CTCs from prostate cancer patients and found that targeted CTC transcriptome profiling may be predictive of therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Peter H. J. Slootbeek, Iris S. H. Kloots, Inge M. van Oort, Leonie I. Kroeze, Jack A. Schalken, Haiko J. Bloemendal, Niven Mehra
Summary: Patients with mCRPC and HRRm can benefit from both PlCh and PARPi, with PlCh inducing less cross-resistance. The order of agents in treatment influenced the PFS, with shorter PFS after PARPi when administered second and shorter PFS after PlCh when administered first. More than 40% of the patients were sensitive to a subsequent HRR-targeting agent. Understanding resistance mechanisms is crucial for determining optimal treatment sequence in HRRm mCRPC patients.
Review
Medical Laboratory Technology
Peter H. J. Slootbeek, Sofie H. Tolmeijer, Niven Mehra, Jack A. Schalken
Summary: The treatment of metastatic castration-resistant prostate cancer has been transformed by precision oncology, aiming to match targeted therapies with tumor genotypes through ctDNA sequencing to monitor treatment response and resistance mechanisms for improved outcomes.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
(2023)
Article
Urology & Nephrology
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N. M. Dinjens, Jurgen Futterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W. J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G. L. Vanneste, Erik Vegt, Andre N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Summary: A group of Dutch specialists discussed the use of germline and tumour genetic testing in prostate cancer (PCa) patients, indication of these tests (which patients and when), and impact of these tests on the management and treatment of PCa.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Meeting Abstract
Oncology
S. van Wilpe, H. Westdorp, I. S. H. Kloots, P. Slootbeek, M. den Brok, G. Adema, L. Kerkmeijer, R. J. Smeenk, M. Coskunturk, H. Bloemendal, J. Schalken, N. V. Erp, W. R. Gerritsen, N. Mehra
ANNALS OF ONCOLOGY
(2022)
Article
Urology & Nephrology
Raquel Carrasco, Mercedes Ingelmo-Torres, Ascension Gomez, Fiorella L. Roldan, Natalia Segura, Maria Jose Ribal, Antonio Alcaraz, Laura Izquierdo, Lourdes Mengual
Summary: We identified the TERT c.-124C > T mutation as a potential biomarker of aggressivity in MIBC patients after RC, and found that CTC enumeration is an independent prognostic biomarker for tumor progression and cancer specific survival. CTC enumeration can detect tumor progression earlier than imaging techniques.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)